Source comparison
CJC-1295 no DAC & Ipamorelin Peptide: Research Comparison
CJC-1295 no DAC & Ipamorelin Dual GHRH/ghrelin receptor agonism 30 min / 2 hours High GH selectivity, no cortisol/prolactin elevation Maximum. Complementary pathways Gold standard for pulsatile GH research. Preserves natural rhythm without receptor desensitiza
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC & Ipamorelin
- Dual GHRH/ghrelin receptor agonism
- 30 min / 2 hours
- High GH selectivity, no cortisol/prolactin elevation
- Maximum. Complementary pathways
- Gold standard for pulsatile GH research. Preserves natural rhythm without receptor desensitization
- CJC-1295 with DAC
- Extended GHRH analog (albumin-bound)
- 6–8 days
- Moderate. Sustained GH elevation
- Low. Continuous receptor occupancy causes downregulation
- Produces tonic GH elevation rather than pulses. Less physiological but simpler dosing
- GHRP-6
- Non-selective ghrelin receptor agonist
- 20–30 min
- Low. Stimulates cortisol, prolactin, and appetite
- Moderate. Amplifies GH but with side-effect burden
- Older secretagogue with broader endocrine effects. Not suitable for chronic use
- Ipamorelin monotherapy
- Selective ghrelin receptor agonist
- 2 hours
- High. Minimal cortisol/prolactin
- Moderate. Effective alone but lower peak amplitude
- Safer alternative to GHRP-6 but produces smaller GH pulses without GHRH priming
- Exogenous GH
- Direct GH receptor agonism
- 2.5–3 hours
- N/A. Replaces endogenous secretion
- None. Suppresses natural pulsatility
- Pharmacological replacement. Not a secretagogue. Downregulates GH receptors over time